Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 24 peer-reviewed journal articles Updated
Oncology · Gastric Neuroendocrine Tumor

Treatment Strategies: Matching Care to Your Tumor Type

At a Glance

The standard treatment for a Gastric Neuroendocrine Tumor (G-NET) depends directly on whether it is Type 1, 2, or 3. Type 1 tumors usually require only minimally invasive endoscopy or observation, while Type 3 tumors are more aggressive and typically need partial or total stomach surgery.

The standard of care for gastric neuroendocrine tumors (G-NETs) is not “one size fits all.” Because G-NETs are divided into three distinct types, the treatment for one patient might be a simple check-up, while for another, it may involve surgery or systemic therapies. Understanding these standard paths can help you ensure your care aligns with current international guidelines [1][2].

Type 1: The “Organ-Preserving” Approach

Since Type 1 G-NETs are usually slow-growing and have an excellent prognosis, the goal of treatment is to remove the tumors while keeping your stomach intact [3][4].

  • Endoscopic Resection (EMR/ESD): Most Type 1 tumors are small (<2 cm) and can be removed during an endoscopy using techniques called Endoscopic Mucosal Resection (EMR) or Endoscopic Submucosal Dissection (ESD) [5][6].
  • Somatostatin Analogs (SSAs): If tumors are too numerous to remove one by one, or if they keep coming back, doctors may use medications like octreotide or lanreotide. These are usually given as a monthly injection. They work by lowering the hormone gastrin and have an “anti-proliferative” effect, meaning they can slow down or stop tumor growth [7][8].
  • Watchful Waiting: For very small, well-differentiated (Grade 1) tumors under 1 cm, some guidelines now suggest that simple observation with regular endoscopies is a safe and feasible option [9][10].

Type 2: Managing the Underlying Syndrome

Type 2 tumors are caused by another tumor (a gastrinoma) pumping out excess hormones. While surgery to remove the primary gastrinoma (often in the pancreas or duodenum) is considered when possible, these tumors are often multifocal or metastatic, making a simple “find and remove” surgery impossible for many patients [11][12]. Instead, many Type 2 patients are successfully managed long-term with medications (like Somatostatin Analogs or high-dose PPIs) to control the excess hormone and acid. When the hormone levels drop, the stomach NETs often shrink or stabilize [2].

Type 3: The “Oncologic” Approach

Type 3 G-NETs are sporadic and more aggressive. Because they have a higher risk of spreading to nearby lymph nodes or distant organs, the treatment is more intensive [13][14].

  • Surgery: For localized tumors, the standard of care is usually a partial or total gastrectomy (removing part or all of the stomach) along with lymph node dissection [13][15].
  • Systemic Therapies: If a Type 3 tumor is advanced, high-grade, or has metastasized (spread), surgery alone is rarely sufficient. Treatments then involve systemic therapies, which may include targeted therapies, chemotherapy, or specialized radioactive treatments like Peptide Receptor Radionuclide Therapy (PRRT) to attack cancer cells throughout the body [13][16].
  • Endoscopic Exception: Occasionally, if a Type 3 tumor is very small (<1-2 cm), low-grade (G1), and has not invaded the muscle layer, it may be considered for endoscopic removal, but this requires a highly specialized team [17][18].

Recognizing Substandard Care

Because G-NETs are rare, some doctors who primarily treat “standard” stomach cancer (adenocarcinoma) may suggest treatments that are outdated or overly aggressive for neuroendocrine tumors.

  • Over-treatment of Type 1: Recommending a total stomach removal (gastrectomy) for small Type 1 G-NETs is generally considered unnecessary and substandard care today [10][19].
  • Under-treatment of Type 3: Attempting to “watch and wait” on a Type 3 tumor without a formal surgical and oncologic evaluation can be dangerous, as these have a much higher risk of metastasis [13].
  • Missing the “Background”: A treatment plan that focuses only on the tumor without testing the rest of the stomach for atrophic gastritis (the cause of Type 1) is incomplete [20][21].

Long-Term Surveillance

Even after successful treatment, lifelong follow-up is standard.

  • Type 1: Typically involves an endoscopy every 12 to 24 months [22].
  • Type 3: Requires more intensive monitoring, often including CT scans, MRIs, or 68Gallium-DOTATATE PET scans every 6 to 12 months to watch for any signs of spread [23][24].

Common questions in this guide

Do I need my entire stomach removed for a Type 1 G-NET?
For most small Type 1 tumors, a total stomach removal is considered unnecessarily aggressive. The standard of care focuses on preserving the stomach using minimally invasive endoscopic removal, hormone-blocking medications, or careful observation.
What are somatostatin analogs and how do they help?
Somatostatin analogs, such as octreotide and lanreotide, are medications given as monthly injections. They help lower hormone levels and have an anti-proliferative effect, meaning they can slow down or stop the growth of tumors in the stomach.
Why does a Type 3 G-NET require more aggressive surgery?
Type 3 tumors are sporadic and much more aggressive than Type 1 or 2, carrying a higher risk of spreading to lymph nodes or distant organs. To prevent this, standard care usually involves an oncologic surgery, such as a partial or total gastrectomy along with lymph node removal.
Is 'watch and wait' a safe option for my stomach tumors?
Yes, some guidelines now support watchful waiting for very small, slow-growing Type 1 tumors that are under one centimeter. This approach involves close observation with regular endoscopies to monitor the tumor without immediately removing it.
How often will I need scans or tests after my treatment is finished?
Lifelong follow-up is necessary after treatment. If you have a Type 1 tumor, you will likely need an endoscopy every one to two years. For Type 3 tumors, doctors use more intensive monitoring, requiring CT scans, MRIs, or specialized PET scans every 6 to 12 months to check for spread.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Given that I have a Type 1 G-NET, is major surgery really necessary, or can we manage this with endoscopic removal?
  2. 2.If we use endoscopic resection (EMR or ESD), how do we confirm that the 'margins' are clear and the entire tumor was removed?
  3. 3.Am I a candidate for somatostatin analogs (octreotide/lanreotide) to help manage the multiple small tumors in my stomach?
  4. 4.What is the specific surveillance schedule we will follow to monitor for recurrence?
  5. 5.How much experience does this surgical/endoscopic team have specifically with neuroendocrine tumors compared to standard stomach cancer?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (24)
  1. 1

    A 15-year experience with gastric neuroendocrine tumors: Does type make a difference?

    Postlewait LM, Baptiste GG, Ethun CG, et al.

    Journal of surgical oncology 2016; (114(5)):576-580 doi:10.1002/jso.24369.

    PMID: 27393718
  2. 2

    GASTRIC NEUROENDOCRINE TUMOR: REVIEW AND UPDATE.

    Dias AR, Azevedo BC, Alban LBV, et al.

    Arquivos brasileiros de cirurgia digestiva : ABCD = Brazilian archives of digestive surgery 2017; (30(2)):150-154 doi:10.1590/0102-6720201700020016.

    PMID: 29257854
  3. 3

    Management of Gastric Neuroendocrine Tumors: A Review.

    Sok C, Ajay PS, Tsagkalidis V, et al.

    Annals of surgical oncology 2024; (31(3)):1509-1518 doi:10.1245/s10434-023-14712-9.

    PMID: 38062290
  4. 4

    Gastric neuroendocrine tumors: 20-Year experience in a reference center.

    Ravizza D, Giunta M, Sala I, et al.

    Journal of neuroendocrinology 2024; (36(12)):e13440 doi:10.1111/jne.13440.

    PMID: 39191460
  5. 5

    Clinical Outcomes of Endoscopic Treatment for Type 1 Gastric Neuroendocrine Tumor.

    Noh JH, Kim DH, Yoon H, et al.

    Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract 2021; (25(10)):2495-2502 doi:10.1007/s11605-021-04997-0.

    PMID: 33825119
  6. 6

    Clinical Outcomes of Endoscopic Resection for Gastric and Duodenal Neuroendocrine Tumors.

    Chang JW, Jung DH, Yoon JH, et al.

    Gut and liver 2026; doi:10.5009/gnl250378.

    PMID: 42349926
  7. 7

    Response and relapse rates after treatment with long-acting somatostatin analogs in multifocal or recurrent type-1 gastric carcinoids: A systematic review and meta-analysis.

    Rossi RE, Invernizzi P, Mazzaferro V, Massironi S

    United European gastroenterology journal 2020; (8(2)):140-147 doi:10.1177/2050640619890465.

    PMID: 32213066
  8. 8

    Personalized treatment of well-differentiated gastric neuroendocrine tumors based on clinicopathological classification and grading: A multicenter retrospective study.

    Huang J, Liu H, Yang D, et al.

    Chinese medical journal 2024; (137(6)):720-728 doi:10.1097/CM9.0000000000003029.

    PMID: 38384175
  9. 9

    The indolent nature of type 1 gastric neuroendocrine tumors under 1 cm.

    Dell'Unto E, Mandair D, Riding G, et al.

    Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver 2026; (58(1)):119-124 doi:10.1016/j.dld.2025.09.011.

    PMID: 41016874
  10. 10

    Therapeutic Challenges for Gastric Neuroendocrine Neoplasms: Take It or Leave It?

    Cavalcoli F, Gallo C, Coltro LA, et al.

    Medicina (Kaunas, Lithuania) 2023; (59(10)) doi:10.3390/medicina59101757.

    PMID: 37893475
  11. 11

    Gastrinomas: Medical or Surgical Treatment.

    Norton JA, Foster DS, Ito T, Jensen RT

    Endocrinology and metabolism clinics of North America 2018; (47(3)):577-601 doi:10.1016/j.ecl.2018.04.009.

    PMID: 30098717
  12. 12

    Gastric Neuroendocrine Tumors (Carcinoids).

    Gluckman CR, Metz DC

    Current gastroenterology reports 2019; (21(4)):13 doi:10.1007/s11894-019-0684-7.

    PMID: 30868284
  13. 13

    Neuroendocrine Tumors of the Stomach.

    Corey B, Chen H

    The Surgical clinics of North America 2017; (97(2)):333-343 doi:10.1016/j.suc.2016.11.008.

    PMID: 28325190
  14. 14

    Gastric carcinoids: Does type of surgery or tumor affect survival?

    Crown A, Kennecke H, Kozarek R, et al.

    American journal of surgery 2019; (217(5)):937-942 doi:10.1016/j.amjsurg.2018.12.057.

    PMID: 30686481
  15. 15

    [A 3mm Gastric Neuroendocrine Tumor That Metastasized to a Lymph Node].

    Fukui Y, Kato Y, Okazaki Y, et al.

    Gan to kagaku ryoho. Cancer & chemotherapy 2018; (45(13)):1839-1841.

    PMID: 30692371
  16. 16

    Comparison of Survival and Patterns of Recurrence in Gastric Neuroendocrine Carcinoma, Mixed Adenoneuroendocrine Carcinoma, and Adenocarcinoma.

    Lin J, Zhao Y, Zhou Y, et al.

    JAMA network open 2021; (4(7)):e2114180 doi:10.1001/jamanetworkopen.2021.14180.

    PMID: 34313744
  17. 17

    Clinicopathological characteristics and prognosis of 77 cases with type 3 gastric neuroendocrine tumours.

    Li YL, Qiu XD, Chen J, et al.

    World journal of gastrointestinal oncology 2020; (12(12)):1416-1427 doi:10.4251/wjgo.v12.i12.1416.

    PMID: 33362912
  18. 18

    Gastric Neuroendocrine Tumors (g-NETs): A Systematic Review of the Management and Outcomes of Type 3 g-NETs.

    Laffi A, Lania AGA, Ragni A, et al.

    Cancers 2023; (15(8)) doi:10.3390/cancers15082202.

    PMID: 37190131
  19. 19

    Insights into gastric neuroendocrine tumors burden.

    Thomaz Araújo TM, Barra WF, Khayat AS, de Assumpção PP

    Chinese journal of cancer research = Chung-kuo yen cheng yen chiu 2017; (29(2)):137-143 doi:10.21147/j.issn.1000-9604.2017.02.06.

    PMID: 28536492
  20. 20

    Unmasking the high-risk phenotype in autoimmune gastritis: A pathologist's roadmap for the clinician.

    Wang CL, Zeng M, Luo Y

    World journal of gastroenterology 2025; (31(48)):115244 doi:10.3748/wjg.v31.i48.115244.

    PMID: 41480315
  21. 21

    Gastric Neuroendocrine Tumors and Pernicious Anemia: A Case Report and Literature Review.

    Rudolph JJ, Agyei O, Telvizian T, Ghaneie A

    Cureus 2024; (16(11)):e73553 doi:10.7759/cureus.73553.

    PMID: 39669826
  22. 22

    Management of type 1 gastric neuroendocrine tumors: an 11-year retrospective single-center study.

    Chen YY, Guo WJ, Shi YF, et al.

    BMC gastroenterology 2023; (23(1)):440 doi:10.1186/s12876-023-03079-6.

    PMID: 38097952
  23. 23

    Advances in Endoscopic Diagnosis and Treatment of Gastric Neuroendocrine Neoplasms.

    Guo X, Zhao X, Huang G, Yu Y

    Digestive diseases and sciences 2024; (69(1)):27-35 doi:10.1007/s10620-023-08180-0.

    PMID: 37971578
  24. 24

    Gastroenteropancreatic Neuroendocrine Tumor Diagnosis: DOTATATE PET/CT.

    Kandathil A, Subramaniam RM

    PET clinics 2023; (18(2)):189-200 doi:10.1016/j.cpet.2022.11.001.

    PMID: 36585339

This page provides information on standard treatment options for Gastric Neuroendocrine Tumors for educational purposes. Always discuss your specific tumor type and treatment plan with a specialized multidisciplinary oncology team.

Get notified when new evidence is published on Neuroendocrine tumor of stomach.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.